Pick up two nattokinase products and one may talk in milligrams while the other talks in FU. The instinct is to convert between them the way you would convert grams to ounces. No dependable public conversion exists to reach for, because the two numbers answer different questions: milligrams describe how much material sits in a serving, and FU describes measured enzyme activity. Working out which question each number answers is most of what reading this ingredient well requires.
The distinction sharpens when a number is built into a product name. Helixa's public catalog currently lists a product titled Helixa Nattokinase 10,000 FU, and you can see the Helixa Nattokinase 10,000 FU catalog listing for the exact wording of that title. A figure like that is a declaration made in activity units by whoever prepared the label. It is not a measurement of what will happen in a person who swallows the capsule, and that gap is the subject of everything below.
Weight answers how much, activity answers how fast
Milligrams are a mass. They tell you what quantity of material went into a serving, which is useful when you want to know how much you are being asked to swallow. What a weight cannot tell you is how enzymatically active that material is, because enzymes are not graded by mass alone.
That is not hypothetical. A 1993 methods paper, The Method of Determination of the Thrombolytic Enzyme Nattokinase, evaluated ways to measure nattokinase activity and reported that measured activity varied across natto samples, including products made with the same Bacillus species. Same species, different measured activity. That kind of variability is exactly why an activity unit exists at all: weight was never going to capture it.
What FU actually abbreviates
FU stands for fibrinolytic units. The expansion is written out plainly in the literature: a double-blind crossover paper describing a nattokinase preparation declared at 2,000 FU spells the abbreviation out as fibrinolytic units when it introduces the material. That paper is cited here for the terminology and nothing more; its small crossover experiment and its outcomes say nothing about any finished supplement.
The unit is tied to an assay rather than to a scale. The 1993 methods work describes a test-tube approach built on fibrin clot lysis time: a clot is formed, the preparation is introduced, and the time the clot takes to break down is recorded. The resulting figure characterises how a sample behaved in glassware under laboratory conditions. That is a different category of statement from anything about a human being, and the label carries the laboratory number, not the human one.
What the randomized trials actually put to the test
Two randomized human trials are worth knowing, mostly because they are so specific about what they examined. The earlier one, published in 2008, was randomized, double-blind and placebo-controlled. It enrolled 86 adults with untreated systolic blood pressure of 130 to 159 mmHg, and 73 completed the protocol. Participants took one nattokinase capsule declared at 2,000 FU daily for eight weeks, and the abstract reported greater reductions in systolic and diastolic blood pressure than placebo. Notice how tightly bounded that sentence is: one declared activity level, one daily capsule, eight weeks, one enrolled group, one measured outcome.
The later trial ran on an entirely different timescale. Published in 2021, it randomized 265 adults without clinical cardiovascular disease to nattokinase declared at 2,000 fibrinolytic units or to placebo, and followed them for a median of three years. The abstract reported no significant difference in the progression of carotid intima-media thickness or carotid arterial stiffness, and no significant effect on blood pressure or on the laboratory measures listed. Reading the two together is clarifying rather than confusing: an eight-week study of one outcome and a three-year study of several others are not competing, and neither answers the other's question.
Where those findings stop
Each trial describes the preparation that was actually administered in it. They are evidence about a defined intervention, in a defined population, over a defined duration, with a defined set of measured outcomes. They are not evidence about the Helixa formula, dose, safety profile or finished-product effects, and no result from either study transfers to a different preparation just because a similar unit appears on both labels. Shared vocabulary is not shared data.
The second constraint concerns what these data can support at all. The three-year results cannot be used to infer disease prevention, medication replacement, or an outcome for a different formula or dose, and the same restraint runs in the other direction for the eight-week blood pressure findings. An activity assay, however carefully performed, measures a sample; it does not promise a result in a person. The honest summary is that ingredient research and finished-product performance are separate subjects, and this article does not join them.
A label reader's checklist
When a nattokinase label is in front of you, a handful of questions keep the numbers honest:
- Is the headline number a weight in milligrams or an activity figure in FU? One does not substitute for the other.
- If FU is given, is the serving it applies to stated clearly?
- Does a milligram figure describe the whole blend or the nattokinase portion?
- Is any method or assay named alongside the activity number?
- Are you looking at a declaration, or at independent verification of one?
- Does the page promise an outcome? Published trials describe what they measured; they do not license a promise.
Reading a declaration as a declaration
Every figure printed on a supplement label, including one embedded in a product title, is a statement made by the seller. The presence of 10,000 FU in a product name tells you what is being declared in activity units. It does not tell you what has been independently confirmed about a physical bottle, and it does not tell you what will happen after a capsule is swallowed. Reading it that way is the same discipline that keeps trial results from being stretched past what they measured.
Looking at the listing yourself
If you would rather check the wording than take a summary's word for it, you can view the product details for Helixa Nattokinase 10,000 FU and read the declaration as it is presented. Nothing in this article evaluates that product's formula, dose, safety or effects; the Helixa editorial team kept those questions out of scope because the sources cited below do not answer them.
Questions worth bringing to a professional
This is an editorial explainer about units and evidence, not medical advice, and it cannot tell you whether any supplement belongs in your life. If you are considering nattokinase in any form, that conversation belongs with a qualified healthcare professional who knows your current medications, your health conditions and your history. Take the label with you, activity and weight figures included, so the discussion is about the specific product in front of you rather than a category.
Sources
- Nattokinase randomized trial (PubMed 18971533) — 2008 randomized, double-blind, placebo-controlled trial; 2,000 FU daily for eight weeks.
- Nattokinase randomized trial (PubMed 33843667) — 2021 double-blind trial; 265 adults, median follow-up of three years.
- A single dose of oral nattokinase accelerates skin temperature recovery after cold water immersion: A double-blind, placebo-controlled crossover study — cited only for its expansion of FU as fibrinolytic units.
- The Method of Determination of the Thrombolytic Enzyme Nattokinase — 1993 methods paper on measuring nattokinase activity.
Related reading from Helixa
Review the product details
Helixa Nattokinase 10,000 FU
Review the declared label, ingredients, serving information, and purchase options on the product page before deciding whether it fits your needs.
